Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
NCT ID: NCT07122635
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2024-10-03
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery
NCT03640351
The Effect of Cyclosporin Before Cataract Surgery
NCT04426240
Refraction Changes After Using ND: YAG LASER In Treatment of Posterior Capsular Opacification In Pseudo Phakic Eye
NCT05501535
Dryness Difference Between Before and After Phacoemulsification
NCT06513000
Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease
NCT06221345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing phacoemulsification surgery and having dry eye 1 week after the surgery
Diquafosol Sodium 3%
Diquafosol Sodium 3% ophthalmic solution, 1 drop each time, 6 times daily, from baseline (1 week after the surgery) to 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diquafosol Sodium 3%
Diquafosol Sodium 3% ophthalmic solution, 1 drop each time, 6 times daily, from baseline (1 week after the surgery) to 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis with grade 1, grade 2 or grade 3 dry eye one week after the surgery according to DEWS 2007 classification and Sullivan's severity grading scheme
Exclusion Criteria
* Phaco surgery with complications during or after surgery
* Patients with other eye surgeries within 6 months before phaco surgery
* Patients who are using other eye drops before phaco surgery, except artificial tears
* Patients with acute eye infections
* Patients who do not return for follow-up appointments
* Patients who do not comply with treatment
* Patients having allergy with diquafosol 3%
* Patients having side effects with diquafosol 3% and do not want to continue using the drug
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Le Xuan Cung
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Le Xuan Cung
Head of Cornea Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vietnam National Eye Hospital
Hanoi, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
764/QD-BVMTW No. 17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.